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OBJECTIVE: The protein Hwp1, expressed on the pathogenic phase of Candida
albicans, presents sequence analogy with the gluten protein gliadin and is also a
substrate for transglutaminase. This had led to the suggestion that C. albicans
infection (CI) may be a triggering factor for Celiac disease (CeD) onset. We
investigated cross-immune reactivity between CeD and CI.
METHODS: Serum IgG levels against recombinant Hwp1 and serological markers of
CeD were measured in 87 CeD patients, 41 CI patients, and 98 healthy controls (HC).
IgA and IgG were also measured in 20 individuals from each of these groups using
microchips sensitized with 38 peptides designed from the N-terminal of Hwp1.
RESULTS: CI and CeD patients had higher levels of anti-Hwp1 (p=0.0005 and
p=0.004) and anti-gliadin (p=0.002 and p=0.0009) antibodies than HC but there was
no significant difference between CeD and CI patients. CeD and CI patients had
higher levels of anti-transglutaminase IgA than HC (p=0.0001 and p=0.0039). During
CI, the increase in anti-Hwp1 paralleled the increase in anti-gliadin antibodies.
Microchip analysis showed that CeD patients were more reactive against some Hwp1
peptides than CI patients, and that some deamidated peptides were more reactive
than their native analogs. Binding of IgG from CeD patients to Hwp1 peptides was
inhibited by γIII gliadin peptides.
CONCLUSIONS: Humoral cross-reactivity between Hwp1 and gliadin was observed
during CeD and CI. Increased reactivity to Hwp1 deamidated peptide suggests that
transglutaminase is involved in this interplay. These results support the hypothesis
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